Posted by Michael Wonder on 21 Dec 2019
FDA approves Ortho Dermatologics' Arazlo (tazarotene) 0.045% lotion, for acne vulgaris
19 December 2019 - First tazarotene acne treatment approved in lotion formulation.
Bausch Health and its dermatology business, Ortho Dermatologics, today announced that the U.S. FDA has approved the New Drug Application for Arazlo (tazarotene) 0.045% lotion, for the topical treatment of acne vulgaris in patients nine years of age and older.
Arazlo is the first tazarotene acne treatment available in a lotion form, and has been shown to provide strong efficacy with favourable tolerability.
